ShoreBank Capital

Shoreline Biosciences is a biotechnology company focused on developing next-generation immunotherapy treatments for cancer and other diseases. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create standardized, "off-the-shelf" natural killer (NK) cell and macrophage therapies. By using advanced gene editing techniques like CRISPR, Shoreline aims to enhance the potency and persistence of these immune cells. The company has established significant strategic partnerships with major pharmaceutical firms, including Gilead Sciences (Kite) and BeiGene, to advance its pipeline of cell-based immunotherapies.